# Microbiome Sequencing Services Market

> Microbiome Sequencing Services Market Research Report Information By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others), By Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 17.7%
- **2024:** $ 2,083.29 Million
- **2025:** $ 2,452.03 Million
- **2035:** $ 12,510.97 Million
- **Key Players:** Illumina(US), Thermo Fisher Scientific (US), Qiagen (DE), Zymo Research (US), Genomatix (DE), Novogene (CN), Macrogen (KR), BaseClear (NL), Molecular Research LP (US)

**Report ID:** MRFR/HC/6063-HCR · **Pages:** 160 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532

---

## Market Summary

## **Global Microbiome Sequencing Services Market Overview**

As per MRFR analysis, the Microbiome Sequencing Services Market Size was estimated at 2.08 (USD Billion) in 2024. The Microbiome Sequencing Services Market Industry is expected to grow from 2.45 (USD Billion) in 2025 to 10.63 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.90% during the forecast period (2025 - 2034). The increased demand for next-generation sequencing, the expansion of microbeam sequencing services, and falling sequencing costs are the key market drivers fostering the growth of the market.

The market is being driven by the rising sales of pharmaceutical products and the advantages of microbiome sequencing for cancer treatment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**At an international conference in October 2024**, Second Genome used data from their in-house sequencing methods to deliver studies showing the therapeutic potential of microbiome modification in malignancy.

**In March 2024, BIOHM Health Inc.,** a company focused on microbiome-based wellness solutions, announced a collaborative effort with Virginia Tech. This partnership aimed to leverage artificial intelligence (AI) to develop and commercialize products based on the analysis of bacterial and fungal microbiomes.

**In April 2024, Microbiome Insights Inc.,** a prominent player in microbiome sequencing and analysis, unveiled its new long-read sequencing services for both 16S rRNA gene and metagenomic analysis [[invalid URL removed]]. This launch aimed to equip researchers with a more powerful tool for understanding the complexities of the microbiome.

## **Microbiome Sequencing Services Market Trends**

Market CAGR for microbiome sequencing services is being driven by the rising price of the advanced infrastructure of sequencing. Next-generation sequencing (NGS) systems, bioinformatics tools, and data storage and analysis capabilities are just a few examples of the sophisticated and pricy technology needed for the field of microbiome sequencing. Many academic and research institutions, pharmaceutical and biotechnology firms, and other end users may find the expense of setting up and maintaining such infrastructure exorbitant. Microbiome sequencing outsourcing enables professionals to access cutting-edge technology and know-how without making substantial upfront investments.

These service providers frequently feature cutting-edge facilities and knowledgeable staff adept at microbiome sequencing utilizing the most recent tools and techniques. Professionals can utilize the skills of these specialized facilities through outsourcing without having to worry about capital costs, operational costs, and maintenance costs related to in-house infrastructure.

The market for microbiome sequencing services is expected to grow due to significant investments in microbiome research. Demand for next-generation sequencing services and genetic research has increased, which is anticipated to benefit the industry. The range of applications for microbiome sequencing is also expanding. The next-generation sequencing technologies show a fundamental shift in the sequencing industry. This technological know-how has been applied to biological study, leading to a surprising and profound grasp of the molecular biology of the cell. Budgets for research and development initiatives have steadily increased over the past ten years.

Every pharmaceutical company wants its products to be successful on the market.

The substantial virus research conducted by the government in collaboration with business stakeholders also contributed to the pandemic's high demand for microbiome sequencing. In the UK, a genome sequencing collaboration was established in March 2020 to enable quick, thorough, and extensive sequencing examination of samples from individuals whose COVID-19 testing was positive. The network will sequence every patient sample that tested positive for the virus. Oxford Nanopore is happy to support the teams in the UK working on this effort. Thus, driving the microbiome sequencing services market revenue.

## **Microbiome Sequencing Services Market Segment Insights**

### **Microbiome Sequencing Services Technology Insights**

The microbiome sequencing services market segmentation, based on technology, includes sequencing by litigation (SBL), sequencing by synthesis (SBS), short gun sequencing, targeted gene sequencing, RNA sequencing, and others. The sequencing by synthesis (SBS)segment dominated the market, accounting for 42.1% of market revenue (0.6 Billion). SBS makes analyzing the microbiome efficient and affordable by concurrently enabling high-throughput sequencing of millions of DNA fragments. Shotgun sequencing applications are used in market segments that are the fastest growing segment. The industry is experiencing increased demand due to its prevalence and the need for efficient treatment methods.

The shotgun accelerates the market's growth rate because it is more practical and affordable than any alternative option.

**Figure 1: Microbiome Sequencing Services Market, by Technology, 2022 & 2034 (USD Billion)**

_Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review_

### **Microbiome Sequencing Services Application Insights**

The microbiome sequencing services market segmentation, based on application, includes [gastrointestinal](../../../reports/gastrointestinal-drugs-market-558) diseases, infectious diseases, cns diseases, [oncology](../../../reports/oncology-information-systems-market-7080), and others. The oncology sector dominates the market for microbiome sequencing services. Because of the increasing number of cancer cases worldwide and the growth of cancer genomic research, the market for microbiome sequencing services is predicted to increase.

**March 2022:** Microbiotica has raised USD 67 million for its study on microbiome-based immuno-oncology, which will begin later this year. Microbiotica's two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310, will be advanced to Phase 1b clinical trials with the funds. MB097 is a fully characterized LBT comprising a consortium of bacteria that form the foundation of Microbiotica's clinical microbiome signature that predicts patient response to Immune Checkpoint Inhibitor medication.

A significant share belonged to the gastrointestinal area. Various gut-related disorders can result from changes in the microbiome, which is crucial for maintaining the health of the digestive system. Researchers have uncovered important microbial species and their roles in the emergence and progression of gut-related disorders thanks to using microbiome sequencing to analyze the gut microbiome.

### **Microbiome Sequencing Services Regional Insights**

By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American microbiome sequencing services market will dominate due to the rise in the adoption of highly advanced techniques and systems in the microbiome sequencing services and technical improvements made in genomic research investigations. The strong market growth in the region is mostly due to the high awareness among medical professionals about the existence of cutting-edge microbiome sequencing services in the market.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

**Figure 2: MICROBIOME SEQUENCING SERVICES MARKET SHARE BY REGION 2022 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

Europe’s microbiome sequencing services market accounts for the second-largest market share. Significant players' presence and increased public awareness of NGS are important drivers of accelerating expansion. The increased use of micro-biomes in genomes, proteomics, and metabolomics is responsible for this region's expansion. Further, the German microbiome sequencing services market held the largest market share, and the UK microbiome sequencing services market was the rapidly growing market in the European region.

The Asia-Pacific Microbiome Sequencing Services Market is expected to grow at a rapid rate from 2023 to 2034. Due to several causes, including increased research funding, increased interest in personalized treatment, and expanding government initiatives to construct cutting-edge healthcare infrastructure, the region's demand for microbiome sequencing services is on the rise. The continual advancement of sequencing technologies and the introduction of novel methods for disease diagnosis are credited with this region's expansion. Moreover, China’s microbiome sequencing services market held the largest market share, and the Indian microbiome sequencing services market was the rapidly growing market in the Asia-Pacific region.

**Microbiome Sequencing Services Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the microbiome sequencing services market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the microbiome sequencing services industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the microbiome sequencing services industry to benefit clients and increase the market sector. In recent years, the microbiome sequencing services industry has offered some of the most significant medical advantages. Major players in the microbiome sequencing services market, including Rancho Biosciences, Metabiomics Corp., EPIBIOME, Baseclear B.V, Microbiome Therapeutics, LLC., and others, are attempting to increase market demand by investing in research and development operations.

Microba Life Sciences Ltd is a commercial-stage firm that uses cutting-edge technology to measure the human gut microbiota and provides gut microbiome testing services to consumers, doctors, and researchers worldwide. Testing Services and Research and Development are two of the company's segments. In February 2023, Microba created a new human gut microbiome testing service to provide comprehensive gastrointestinal testing options. The new human gut microbiome testing product range, launched in Australia, delivers diagnostic gastrointestinal health testing and metagenomic-driven gut microbiome analysis to provide healthcare practitioners with comprehensive gastrointestinal testing solutions.

OraSure Technologies develops, manufactures, and distributes oral fluid diagnostic and collecting systems. Diagnostics and molecular solutions are its reportable segments. The diagnostics branch creates rapid oral diagnostic tests and tools for collecting samples for infectious diseases, including HIV and HCV. In March 2022, OraSure Technologies, Inc. introduced a new service to deliver metatranscriptomic sequencing and analysis of gut microbiome samples through its Diversigen subsidiary.

The metatranscriptomic services will build a gene expression profile of a microbial community to inform clients about the interactions between a human and their microbiome and provide a comprehensive picture of a sample's microbial functions and expression levels.

**Key Companies in the microbiome sequencing services market include**

**Microbiome Sequencing Services Industry Developments**

**January 2022:**Eagle Genomics and Quadram Institute have formed a new strategic alliance to speed up microbiome analysis using an AI-augmented knowledge discovery platform and genetic sequencing technology. The collaboration with the Quadram Institute will involve the sharing of datasets, tools, and innovation pipelines to aid in the understanding of complex microbiome data through Eagle Genomics' e[datascientist] platform, building on the agreement with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research.

**June 2021**:Illumina and Microba Life Sciences have formed a collaboration to better study the role of the human gut microbiome in human health and illness. The collaboration will combine Illumina's ground-breaking NGS techniques with Microba's high-quality proprietary gut microbiome analysis platform to generate the precise metagenomic data researchers need to fuel new discoveries.

## **Microbiome Sequencing Services Market Segmentation**

### **Microbiome Sequencing Services Technology Outlook**

### **Microbiome Sequencing Services Application Outlook**

### **Microbiome Sequencing Services Regional Outlook**

## Market Drivers

### Market Growth Projections

The Global Microbiome Sequencing Services Market Industry is projected to witness substantial growth over the coming years. The market is expected to reach 2.08 USD Billion in 2024 and is forecasted to expand to 11.7 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 16.99% from 2025 to 2035. Such projections indicate a robust demand for microbiome sequencing services, driven by advancements in technology, increased research funding, and a growing consumer focus on health and wellness.

### Increased Research Funding

The Global Microbiome Sequencing Services Market Industry benefits from increased funding for microbiome research from both public and private sectors. Governments and research institutions are recognizing the potential of microbiome studies in various fields, including medicine, agriculture, and environmental science. This influx of funding is facilitating large-scale studies and collaborations, thereby expanding the scope of microbiome research. As a result, the demand for sequencing services is expected to rise, contributing to a compound annual growth rate of 16.99% from 2025 to 2035.

### Growing Awareness of Gut Health

There is a growing awareness of the importance of gut health among consumers, which is significantly influencing the Global Microbiome Sequencing Services Market Industry. As individuals become more informed about the link between gut microbiota and overall health, they are increasingly seeking microbiome testing services. This trend is reflected in the rising number of companies offering consumer-oriented microbiome sequencing services. The increasing consumer demand for gut health insights is likely to drive market expansion, as more individuals seek personalized recommendations based on their microbiome profiles.

### Advancements in Sequencing Technologies

Technological advancements in sequencing methodologies are propelling the Global Microbiome Sequencing Services Market Industry forward. Innovations such as next-generation sequencing (NGS) and single-cell sequencing are enhancing the accuracy and efficiency of microbiome analysis. These technologies enable researchers and clinicians to obtain comprehensive microbial profiles, which are essential for understanding complex interactions within the microbiome. As these technologies continue to evolve, they are likely to attract more investments and drive market growth, potentially leading to a market size of 11.7 USD Billion by 2035.

### Rising Demand for Personalized Medicine

The Global Microbiome Sequencing Services Market Industry is experiencing a notable increase in demand for personalized medicine. This trend is largely driven by the growing recognition of the microbiome's role in health and disease. As healthcare providers seek to tailor treatments based on individual microbiome profiles, the market is projected to reach 2.08 USD Billion in 2024. This shift towards personalized healthcare solutions indicates a significant opportunity for microbiome sequencing services, as they provide critical insights that can enhance therapeutic efficacy and patient outcomes.

### Regulatory Support for Microbiome Research

Regulatory bodies are increasingly supporting microbiome research, which is positively impacting the Global Microbiome Sequencing Services Market Industry. Initiatives aimed at promoting microbiome studies and establishing guidelines for microbiome-based products are fostering a conducive environment for innovation. This regulatory support not only encourages research but also enhances public trust in microbiome-related products and services. As regulations evolve, they may facilitate market entry for new players and technologies, further stimulating growth in the microbiome sequencing services sector.

## Future Outlook

The Microbiome Sequencing Services Market is projected to grow at a 17.7% CAGR from 2025 to 2035, driven by advancements in [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), increasing research funding, and rising consumer awareness.

**New opportunities:**

- Development of integrated microbiome analysis platforms for clinical applications. Expansion of subscription-based microbiome testing services for consumers. Partnerships with pharmaceutical companies for microbiome-related drug development.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Clinical Diagnostics (Largest) vs. Research and Development (Fastest-Growing)

In the Microbiome Sequencing Services Market, the application segments are diverse, with Clinical Diagnostics leading in market share. This segment has gained significance due to the increasing recognition of microbiomes in disease detection and treatment. Following closely is Research and Development, which has gained traction as more organizations invest in innovative microbiome research to enhance healthcare outcomes. Personalized Medicine also plays a notable role, bridging the gap between genetic testing and tailored health strategies. As the Microbiome Sequencing Services Market evolves, growth trends indicate that Research and Development is experiencing the fastest expansion. This surge can be attributed to advancements in technology, coupled with growing research initiatives focused on understanding the microbiome's role in health and disease. Similarly, Personalized Medicine is poised for growth, given its potential to revolutionize treatment strategies based on individual microbiome profiles, while the Agricultural Microbiome and Environmental Monitoring segments are steadily gaining attention for their essential roles in sustainable practices and biodiversity assessment.

Clinical Diagnostics (Dominant) vs. Research and Development (Emerging)

Clinical Diagnostics remains a dominant force in the Microbiome Sequencing Services Market, largely due to its critical role in detecting diseases through microbiome analysis. This segment leverages advanced sequencing technologies to offer insights into patient health, leading to improved diagnostic capabilities and treatment plans. In contrast, Research and Development is emerging as a pivotal segment, driven by the need for groundbreaking studies that explore the complex interactions between microbiomes and health outcomes. Institutions and organizations are increasingly investing in microbiome research, aiming to uncover new therapeutic avenues. Together, these segments highlight the diversity and potential of microbiome sequencing, catering to critical needs in health diagnostics while fostering innovation in research.

### By Technology: 16S rRNA Sequencing (Largest) vs. Shotgun Sequencing (Fastest-Growing)

In the Microbiome Sequencing Services Market, 16S rRNA sequencing currently dominates the landscape due to its established protocols and accuracy in determining microbial diversity. This method enjoys the largest market share, appealing to researchers and healthcare providers focused on microbiome studies. On the other hand, shotgun sequencing, while smaller in share, is rapidly gaining traction. Its ability to sequence entire communities of microorganisms provides deeper insights, making it increasingly preferable among researchers pursuing comprehensive analyses of microbiomes.

Technology: 16S rRNA Sequencing (Dominant) vs. Shotgun Sequencing (Emerging)

16S rRNA sequencing is characterized by its specificity towards bacterial identification and is favored for its cost-effectiveness and reliability. It serves as a crucial method for examining microbial compositions in various environments, from ecological studies to clinical diagnostics. In contrast, shotgun sequencing emerges as a comprehensive approach allowing deeper sequencing of all genetic material from the sample. This technology is gaining momentum due to its versatility in analyzing complex microbiomes, making it particularly appealing for advanced research applications and providing richer genomic insights.

### By End Use: Healthcare (Largest) vs. Pharmaceuticals (Fastest-Growing)

In the Microbiome Sequencing Services Market, the healthcare sector holds the largest market share, driven by its extensive applications in disease diagnosis and treatment personalization. Following closely is the pharmaceuticals segment, which is experiencing rapid growth as companies increasingly focus on microbiome-based therapies and drug development tailored to individual microbiome profiles. Agriculture and environmental services are also significant, but their share is comparatively smaller due to emerging developments in microbiome research.

Healthcare: Diagnostics (Dominant) vs. Pharmaceuticals: Drug Development (Emerging)

The healthcare segment is robust, characterized by a substantial focus on diagnostics and patient treatment methodologies driven by microbiome insights. Dominating this market, diagnostics leverage microbiome analysis to enhance accuracy in disease detection. In contrast, the pharmaceuticals segment, recognized as emerging, is swiftly adapting to new biological insights, focusing on drug development. This sector is pivotal for developing innovative therapies that consider individual microbiomes, marking a transformative approach in treatment personalization. Both segments are instrumental in advancing the microbiome's understanding and application, though the healthcare sector currently leads in adoption.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the microbiome sequencing services market, holding a significant microbiome sequencing services market share. The region's growth is driven by increasing investments in biotechnology, a robust healthcare infrastructure, and rising consumer awareness regarding personalized medicine. Regulatory support from agencies like the FDA further catalyzes innovation and adoption of microbiome technologies. The competitive landscape is characterized by key players such as Illumina, Thermo Fisher Scientific, and Zymo Research, which are at the forefront of technological advancements. The U.S. leads the market, supported by a strong research base and collaborations between academia and industry. This synergy fosters a dynamic environment for new product development and market expansion.

### Europe : Emerging Market with Potential

Europe is witnessing growth supported by strong research initiatives and evolving microbiome sequencing services market trends. The region benefits from strong governmental support for research initiatives and a focus on healthcare innovation. Increasing prevalence of chronic diseases and a shift towards preventive healthcare are key drivers of demand. Regulatory frameworks are evolving to facilitate the integration of microbiome data into clinical practice, enhancing market growth. Leading countries such as Germany, the UK, and France are at the forefront of this market, hosting numerous research institutions and biotech firms. Companies like Qiagen and Genomatix are pivotal in advancing sequencing technologies. The competitive landscape is vibrant, with collaborations between public and private sectors driving innovation and expanding service offerings.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is emerging as a significant player in the microbiome sequencing services market, with a valuation of around 300.0 million in 2024. The region's growth is driven by increasing investments in healthcare infrastructure, rising awareness of microbiome research, and a growing number of research initiatives. Governments are also implementing policies to support biotechnology advancements, which are expected to further stimulate market growth. Countries like China, Japan, and South Korea are leading the charge, with companies such as Novogene and Macrogen playing pivotal roles. The competitive landscape is characterized by a mix of local and international players, fostering innovation and collaboration. As the market evolves, the focus on personalized medicine and health management is likely to drive further expansion.

### Middle East and Africa : Niche Market with Opportunities

The Middle East and Africa region is gradually emerging in the Microbiome Sequencing Services Market, with a market size of $83.97M. This region is gradually developing, supported by increasing microbiome sequencing services market statistics and healthcare investments. The growth is driven by increasing investments in healthcare and biotechnology, alongside a rising focus on personalized medicine. Governments are beginning to recognize the potential of microbiome research, leading to supportive policies and funding initiatives that encourage innovation in this field. Countries like South Africa and the UAE are taking the lead in establishing research facilities and partnerships with global firms. The competitive landscape is still developing, with local players and international companies exploring opportunities to expand their presence. This region holds significant potential for growth as awareness and demand for microbiome services continue to rise.

## Competitive Benchmarking

The Microbiome Sequencing Services Market is currently characterized by a dynamic competitive landscape, driven by advancements in genomic technologies and an increasing focus on personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Novogene (CN) are at the forefront, leveraging their technological prowess and extensive product portfolios to capture market share. Illumina (US) has positioned itself as a leader through continuous innovation in sequencing technologies, while Thermo Fisher Scientific (US) emphasizes its comprehensive suite of solutions for microbiome analysis, enhancing its operational focus on customer-centric services. Novogene (CN), on the other hand, is expanding its global footprint, particularly in Asia, to tap into emerging markets, thereby shaping the competitive environment through strategic regional expansion. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with a mix of established players and emerging companies vying for dominance. The collective influence of these key players is significant, as they drive technological advancements and set industry standards, thereby shaping the overall market structure. In November 2025, Illumina (US) announced a partnership with a leading healthcare provider to integrate its microbiome sequencing services into routine clinical practice. This strategic move is likely to enhance patient outcomes by enabling more precise diagnostics and personalized treatment plans, thereby reinforcing Illumina's position as a pioneer in the field. The collaboration underscores the growing recognition of microbiome analysis in clinical settings, potentially setting a precedent for future partnerships. In October 2025, Thermo Fisher Scientific (US) launched a new line of microbiome [sequencing kit](https://www.marketresearchfuture.com/reports/sequencing-kits-market-40130)s designed for high-throughput applications. This introduction is significant as it caters to the increasing demand for scalable solutions in microbiome research, allowing researchers to conduct large-scale studies with greater efficiency. The move not only strengthens Thermo Fisher's product offerings but also positions the company to capitalize on the growing trend of large-scale microbiome studies. In September 2025, Novogene (CN) expanded its laboratory facilities in Europe, aiming to enhance its service capabilities and meet the rising demand for microbiome sequencing in the region. This expansion is indicative of Novogene's commitment to increasing its operational capacity and improving service delivery, which may provide a competitive edge in the European market. The strategic investment reflects a broader trend of companies seeking to establish a stronger presence in key geographical areas. As of December 2025, the competitive trends in the Microbiome Sequencing Services Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and deliver high-quality, reliable services.

## Recent News & Developments

Strategic collaborations and technological advancements continue to shape the microbiome sequencing services market reports, enhancing innovation and global expansion.

**January 2022:**Eagle Genomics and Quadram Institute have formed a new strategic alliance to speed up microbiome analysis using an AI-augmented knowledge discovery platform and genetic sequencing technology. The collaboration with the Quadram Institute will involve the sharing of datasets, tools, and innovation pipelines to aid in the understanding of complex microbiome data through Eagle Genomics' e[datascientist] platform, building on the agreement with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research.

**June 2021**:Illumina and Microba Life Sciences have formed a collaboration to better study the role of the human gut microbiome in human health and illness. The collaboration will combine Illumina's ground-breaking NGS techniques with Microba's high-quality proprietary gut microbiome analysis platform to generate the precise metagenomic data researchers need to fuel new discoveries.

## Report Scope

| MARKET SIZE 2024 | 2083.29(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2452.03(USD Million) |
| MARKET SIZE 2035 | 12510.97(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Qiagen (DE), Zymo Research (US), Genomatix (DE), Novogene (CN), Macrogen (KR), BaseClear (NL), Molecular Research LP (US) |
| Segments Covered | Application, Technology, End Use |
| Key Market Opportunities | Advancements in personalized medicine drive demand for Microbiome Sequencing Services Market innovations and applications. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in microbiome sequencing services. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Microbiome Sequencing Services Market by 2035?**
A: The projected market valuation for the Microbiome Sequencing Services Market is 12510.97 USD Million by 2035.

**Q: Which companies are considered key players in the Microbiome Sequencing Services Market?**
A: Key players in the market include Illumina, Thermo Fisher Scientific, Qiagen, Zymo Research, Genomatix, BGI Genomics, Novogene, Macrogen, and Oxford Nanopore Technologies.

**Q: What was the market valuation of the Microbiome Sequencing Services Market in 2024?**
A: The overall market valuation of the Microbiome Sequencing Services Market was 2083.29 USD Million in 2024.

**Q: What is the expected CAGR for the Microbiome Sequencing Services Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Microbiome Sequencing Services Market during the forecast period 2025 - 2035 is 17.7%.

**Q: How does the Clinical Diagnostics segment perform in terms of market valuation?**
A: The Clinical Diagnostics segment had a valuation of 500.0 USD Million in 2024 and is projected to reach 3000.0 USD Million by 2035.

**Q: What are the key applications of microbiome sequencing services?**
A: Key applications of microbiome sequencing services include Clinical Diagnostics, Research and Development, Personalized Medicine, Agricultural Microbiome, and Environmental Monitoring.

**Q: Which technology segment is expected to show the highest growth in the Microbiome Sequencing Services Market?**
A: The Shotgun Sequencing technology segment is expected to show the highest growth, with a valuation of 683.29 USD Million in 2024 and a projected 4110.97 USD Million by 2035.

**Q: What is the market valuation for the Environmental Monitoring segment in 2024?**
A: The Environmental Monitoring segment had a valuation of 283.29 USD Million in 2024.

**Q: How does the Pharmaceuticals end-use segment compare to others in market valuation?**
A: The Pharmaceuticals end-use segment had a valuation of 500.0 USD Million in 2024, indicating a strong position within the market.

**Q: What is the projected valuation for the Agricultural Microbiome segment by 2035?**
A: The Agricultural Microbiome segment is projected to reach a valuation of 1800.0 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532*